Managing PAH in patients with parenchymal lung disease
The results of this study by Madden and associates suggest that sildenafil may be useful in managing pulmonary arterial hypertension (PAH) in select patients with parenchymal lung disease.
The results of this study by Madden and associates suggest that sildenafil may be useful in managing pulmonary arterial hypertension (PAH) in select patients with parenchymal lung disease.
The study included 4 patients with end-stage chronic obstructive pulmonary disease (COPD) and 3 with idiopathic pulmonary fibrosis, ranging in age from 68 to 86 years. All had PAH, and none had thromboembolic disease. The patients underwent right heart catheterization, echocardiography, and a 6-minute walk test before and after 8 weeks of treatment with sildenafil.
After treatment, pulmonary vascular resistance was reduced and performance on the 6-minute walk test was improved in 6 of the patients. Echocardiography demonstrated a reduction in estimated pulmonary artery pressure in 6 patients, and an improved right ventricular systolic function in 2 COPD patients.
FDA Accepts Protocol for Annovis Bio’s Buntanetap Phase 3 Alzheimer Disease Trial
January 9th 2025Buntanetap is an oral molecule designed to inhibit the production of multiple neurotoxic proteins and is under investigation for treatment of Alzheimer Disease, Parkinson’s Disease, and other neurodegenerative diseases.
